The biopharma industry in Asia is an exciting one. Despite uncertainty caused by a fragmented marketplace and different regulatory systems, innovators constantly overcome market challenges and produce useful inventions which brings the development of the industry to the next greater level. Among these is Immunwork, a Taiwanese biotech company which created an invention, T-E™ , a molecule containing both targeting (T) and effector (E) moieties for applications in cancer, autoimmune, infectious, and CNS diseases. The T and E modules, which are based on multi-arm linker units, are constructed separately and then joined together by click chemistry.

Germantown, MD, USA  (April 4, 2016) – SyneuRx announced today, the U.S.

FDA’s approval of their newest IND program, SND14, to develop a treatment for mild dementia. SyneuRx will go directly to late phase clinical development with a PII/III adaptive design trial for its mild dementia indication.